Cited by 23Ovarian function and disordersDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Increased mean glucose levels in patients with polycystic ovary syndrome and hyperandrogenemia as determined by continuous glucose monitoring

Open access
ZHU, JIE‐PING, TENG, YIN‐CHENG, ZHOU, JIAN, LU, WEI, TAO, MIN‐FANG, JIA, WEI‐PING·2013·Acta Obstetricia et Gynecologica Scandinavica

Abstract

Objective. Women with polycystic ovary syndrome are at risk of developing type 2 diabetes mellitus. This study aimed to evaluate the influence of hyperandrogenemia on glucose metabolism in polycystic ovarian syndrome patients. Design. Cohort study. Setting. Reproductive Endocrinology Clinic of the Shanghai Sixth People's Hospital. Sample. Fifty‐three patients were recruited from June 2008 to December 2009, including 28 women with hyperandrogenism and 25 without hyperandrogenemia. Methods. Anthropometric parameters, including weight, height, body mass index and waist‐to‐hip ratio, as well as sex hormones, were measured. An oral glucose tolerance test, including fasting and two hour glucose and insulin levels, was recorded. Insulin resistance was evaluated by homeostatic model assessment of insulin resistance, and patients underwent continuous glucose monitoring. Main outcome measures. Mean blood glucose level, mean amplitude of glycemic excursion, frequency of glycemic excursion and the percentage of time of hypoglycemia and hyperglycemia during a 48 h period. Results. No differences in age, body mass index, waist‐to‐hip ratio, fasting and two hour glucose and insulin concentrations were observed between the groups. The hyperandrogenism group had higher levels of luteinizing hormone and dehydroepiandrosterone sulfate (p < 0.05). However, continuous glucose monitoring showed that the minimal blood glucose and mean blood glucose were significantly higher in hyperandrogenemia group (p = 0.004). The percentage of time for hypoglycemia (≤70 mg/dL) was higher in the hyperandrogenemia group (p = 0.002). Conclusions. Polycystic ovarian syndrome patients with hyperandrogenemia had an increased mean glucose value, which may place them at increased risk for developing type 2 diabetes.

Overview

Integrity signals

Registry

Crossref · 10.1111/aogs.12031

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ten studies included information regarding the use of wearables.

    “Ten studies included information regarding the use of wearables [77,78,79,80,81,82,83,84,85,86] (Supplementary File S3).”
  • Publication dates of wearable studies spanned from 2009 to 2022, with three originating from China, two from Brazil, two from the USA, and one each from Croatia, Poland, and the UK.

    “Publication dates spanned from 2009 to 2022, with three of them originating from China [81,85,86], two from Brazil [78,82], two from the USA [77], and one each from Croatia [84], Poland [83], and the UK [80].”

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 45

  1. 10.1210/jcem.84.11.6148 · DOI
  2. 10.1210/jc.85.7.2434 · DOI
  3. 10.1210/jc.2005-2430 · DOI
  4. 10.1093/humrep/deh098 · DOI · Paper page
  5. 10.1210/jc.2007-1343 · DOI
  6. 10.1111/j.1365-2265.2007.02764.x · DOI · Paper page
  7. 10.1093/humrep/der065 · DOI
  8. 10.1097/01.OGX.0000109523.25076.E2 · DOI · Paper page
  9. 10.1016/j.beem.2006.02.003 · DOI
  10. 10.1210/jc.83.6.2001 · DOI · Paper page
  11. 10.1046/j.1365-2265.2003.01842.x · DOI
  12. 10.1093/humrep/dem356 · DOI
  13. 10.3109/09513590.2010.551566 · DOI
  14. 10.1055/s-0031-1279740 · DOI
  15. 10.1186/1477-7827-8-142 · DOI
  16. 10.2174/157339906775473635 · DOI
  17. 10.1530/EJE-10-0205 · DOI
  18. 10.2337/dc08-S055 · DOI · Paper page
  19. 10.1089/dia.2005.7.770 · DOI
  20. 10.2337/diacare.28.5.1231 · DOI
  21. 10.1089/dia.2008.0016 · DOI
  22. 10.2337/dc09-0076 · DOI
  23. 10.1089/dia.2007.0293 · DOI
  24. 10.1371/journal.pone.0028312 · DOI
  25. 10.1089/dia.2010.0247 · DOI
  26. 10.3810/pgm.2011.03.2277 · DOI · Paper page
  27. 10.2337/diab.19.9.644 · DOI
  28. 10.1530/eje.1.02058 · DOI
  29. 10.1016/j.fertnstert.2008.12.138 · DOI
  30. Mehrabian F, 2011, The prevalence of metabolic syndrome and insulin resistance according to the phenotypic subgroups of polycystic ovary syndrome in a representative sample of Iranian females, J Res Med Sci., 16, 763
  31. 10.1089/jwh.2010.2053 · DOI
  32. Pelusi B, 2004, Type 2 diabetes and the polycystic ovary syndrome, Minerva Ginecol., 56, 41
  33. 10.1016/j.tem.2007.08.001 · DOI · Paper page
  34. Talbott EO, 2008, Is there an independent effect of polycystic ovary syndrome (PCOS) and menopause on the prevalence of subclinical atherosclerosis in middle aged women, Vasc Health Risk Manag., 4, 453, 10.2147/VHRM.S1452 · DOI
  35. 10.2337/diacare.27.4.861 · DOI · Paper page
  36. 10.1007/s12291-010-0090-2 · DOI
  37. 10.1016/j.fertnstert.2008.04.067 · DOI · Paper page
  38. 10.1111/j.1471-0528.2009.02347.x · DOI
  39. 10.1016/j.ijgo.2009.09.021 · DOI
  40. 10.1111/j.1447-0756.2010.01478.x · DOI
  41. 10.1016/S0301-2115(01)00458-4 · DOI
  42. 10.1097/AOG.0b013e31822c887f · DOI · Paper page
  43. 10.2337/dc06-1612 · DOI · Paper page
  44. 10.1507/endocrj.EJ11-0036 · DOI
  45. 10.1186/1475-2840-10-19 · DOI

Cited by

Sorted by citations

Metadata

Authors
ZHU, J., TENG, Y., ZHOU, J., LU, W., TAO, M., & JIA, W.
Affiliations
Shanghai Jiao Tong University (CN)
Venue
Acta Obstetricia et Gynecologica Scandinavica
Publisher
Wiley
Published
2012-12-05
Volume
92
Issue
2
Pages
165-171
ISSN
  • 0001-6349 (ISSN-L)
  • 1600-0412
OpenAlex
W2136320218
Cited by
23
References
1
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 3 · 2021: 2 · 2019: 2 · 2016: 1 · 2014: 1
FWCI
0.37
Type
journal article
Language
en
Open access
Locations
  • Acta Obstetricia Et Gynecologica Scandinavica (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
polycystic ovary syndrome, hyperandrogenemia, type 2 diabetes risk, continuous glucose monitoring, mean blood glucose, hypoglycemia, glycemic excursions, insulin resistance, luteinizing hormone, dehydroepiandrosterone sulfate
MeSH terms
Adult, Blood Glucose, Diabetes Mellitus, Type 2, Female, Humans, Insulin Resistance, Luteinizing Hormone, Polycystic Ovary Syndrome, Comorbidity, Body Mass Index, Hyperandrogenism, Dehydroepiandrosterone Sulfate, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review